학술논문
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Document Type
Original Paper
Author
Yu, Ming-Lung; Tai, Chi‐Ming; Mo, Lein-Ray; Kuo, Hsing-Tao; Huang, Chung-Feng; Tseng, Kuo-Chih; Lo, Ching-Chu; Bair, Ming-Jong; Wang, Szu-Jen; Huang, Jee-Fu; Yeh, Ming-Lun; Chen, Chun-Ting; Tsai, Ming-Chang; Huang, Chien-Wei; Lee, Pei-Lun; Yang, Tzeng-Hue; Huang, Yi-Hsiang; Chong, Lee-Won; Chen, Chien-Lin; Yang, Chi-Chieh; Hung, Chao-Hung; Yang, Sheng‐Shun; Cheng, Pin-Nan; Hsieh, Tsai-Yuan; Hu, Jui-Ting; Wu, Wen-Chih; Cheng, Chien-Yu; Chen, Guei-Ying; Zhou, Guo-Xiong; Tsai, Wei-Lun; Kao, Chien-Neng; Lin, Chih-Lang; Wang, Chia-Chi; Lin, Ta-Ya; Lin, Chih‐Lin; Su, Wei-Wen; Lee, Tzong-Hsi; Chang, Te-Sheng; Liu, Chun-Jen; Dai, Chia-Yen; Chen, Chi-Yi; Kao, Jia-Horng; Lin, Han-Chieh; Chuang, Wan-Long; Peng, Cheng-Yuan
Source
Hepatology International. 18(2):461-475
Subject
Language
English
ISSN
1936-0533
1936-0541
1936-0541
Abstract
Background: Both European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) guidelines recommend simplified hepatitis C virus (HCV) treatment with pan-genotypic sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for eligible patients. This observational study used real-world data to assess these regimens’ safety in eligible patients and develop an algorithm to identify patients suitable for simplified treatment by non-specialists.Methods: 7,677 HCV-infected patients from Taiwan Hepatitis C Registry (TACR) who received at least one dose of sofosbuvir/velpatasvir or glecaprevir/pibrentasvir, and fulfilled the EASL/AASLD-IDSA criteria for simplified treatment were analyzed. Multivariate analysis was conducted on patient characteristics and safety data.Results: Overall, 92.8% (7,128/7,677) of patients achieved sustained virological response and only 1.9% (146/7,677) experienced Grades 2–4 laboratory abnormalities in key liver function parameters (alanine aminotransferase, aspartate aminotransferase, and total bilirubin), with only 18 patients (0.23%) experiencing Grades 3–4 abnormalities. Age > 70 years old, presence of hepatocellular carcinoma, total bilirubin > 1.2 mg/dL, estimated glomerular filtration rate < 60 mL/min/1.73 m2 , and Fibrosis-4 > 3.25 were associated with higher risks of Grades 2–4 abnormalities. Patients with any of these had an odds of 4.53 times than that of those without in developing Grades 2–4 abnormalities (p < 0.01).Conclusions: Real-world data from Taiwan confirmed that simplified HCV treatment for eligible patients with pan-genotypic regimens is effective and well tolerated. The TACR algorithm, developed based on this study’s results, can further identify patients who can be safely managed by non-specialist care.Graphical Abstract: